Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
This story comes from CNBC's feed; the full article and all rights belong to the source.
Comments (0)
No comments yet. Be the first to comment.
Sign in to write a comment.